<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url><loc>https://psiconautica.org/en/news/psilocybin-parkinsons-inflammatory-markers-uncontrolled-pilot-english/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-29T11:42:09+01:00</news:publication_date><news:title>Psilocybin and Parkinson&#039;s: lower blood inflammatory markers in 9 patients, with no control group</news:title></news:news><image:image><image:loc>https://psiconautica.org/wordpress/wp-content/uploads/2026/10/psico-daily-34264-scaled.jpg</image:loc></image:image></url>
  <url><loc>https://psiconautica.org/en/news/intranasal-mebufotenin-treatment-resistant-depression-phase-2b-jama-english/</loc><news:news><news:publication><news:name>Psiconáutica</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-29T11:42:07+01:00</news:publication_date><news:title>Intranasal mebufotenin in treatment-resistant depression: a 193-adult phase 2b trial</news:title></news:news><image:image><image:loc>https://psiconautica.org/wordpress/wp-content/uploads/2026/10/psico-daily-34260-scaled.jpg</image:loc></image:image></url>
</urlset>